Cargando…
MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers
Chemo-resistance is an important barrier to effective treatment of ovarian cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors are currently promising targeted drugs used to treat BRCA-mutant ovarian cancer. Ovarian cancer patients with BRCA 1/2 mutations appear to benefit better from PARP inhibi...
Autores principales: | Sun, Yue, Wu, Jing, Dong, Xiaoying, Zhang, Jingzi, Meng, Chao, Liu, Guoyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770486/ https://www.ncbi.nlm.nih.gov/pubmed/33360300 http://dx.doi.org/10.1016/j.tranon.2020.100987 |
Ejemplares similares
-
MicroRNA-506-3p inhibits ovarian cancer metastasis by down-regulating the expression of EZH2
por: Sun, Yue, et al.
Publicado: (2022) -
MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2
por: Zhang, Yi, et al.
Publicado: (2015) -
PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
por: Mann, Minakshi, et al.
Publicado: (2019) -
Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
por: Mann, Minakshi, et al.
Publicado: (2019) -
MicroRNA‑506 regulates apoptosis in retinoblastoma cells by targeting sirtuin 1
por: Song, Zhidu, et al.
Publicado: (2019)